New cytoprotector developed and patented in Central Russia

Medbiopharm, a biotech company in Central Russia, has developed and obtained a Russian patent for a pharma substance that is believed to protect the body against chemotherapeutic agents? adverse effects.

Medbiopharm, an R&D-focused biotech company in the Kaluga region?s Obninsk, in Central Russia, announced earlier this spring that it has developed and obtained a Russian patent for a pharma substance that is believed to be able to neutralize adverse effects of ionizing radiation and cytotoxic impact that chemotherapeutic agents typically have on the human body. The new composition is expected to lower the side effects of chemo- and radiation therapies on primarily oncology patients. It is also said to be able to help increase the effectiveness of a therapy. The developers have found that their substance, which is a new cytoprotector, is also capable of enhancing action of some anti-tumor drugs. In addition, the molecule at the heart of the new clathrate complex is assumed to possess powerful antioxidant, immunomodulatory and hepatoprotective properties, which may suggest much broader applications for the composition...